Epitaz 50mg Injection contains Epirubicin, a chemotherapeutic medication of the anthracycline class used to treat several kinds of malignancies.

Brand Name: Epitaz

Composition: Epirubicin

Mechanism of Action:

Epirubicin works through multiple mechanisms to exert its anticancer effects. It interferes with the transcription and replication processes necessary for cell life by intercalating into DNA and preventing the creation of both DNA and RNA. It further impairs cellular activity by inhibiting the enzyme topoisomerase II, which causes DNA strand breaks. Additionally, epirubicin produces free radicals that harm biological components and cause cytotoxicity. Together, these factors prevent cancer cells from proliferating, which eventually results in cell death.

Uses:

·       Breast cancer

·       Ovarian cancer

·       Lung cancer

·       Gastric cancer

·       Bladder cancer

Dosage and Administration:

Administered by IV infusion or gradual injection. should only be used under a qualified oncology professional's supervision.

Side Effects:

·       Myelosuppression

·       Nausea

·       Vomiting

·       Hair loss

·       Mouth sores

·       Red discoloration of urine

Safety Advise:

Lungs  

The safety of Epitaz Injection for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Epitaz Injection for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Epitaz Injection for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Epitaz should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Epitaz while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Store in a refrigerator between 2°C and 8°C. Avoid freezing.

References:

1.     Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. Journal of Clinical Oncology. 1986 Mar;4(3):425-39.

2.     Conte PF, Gennari A, Landucci E, Orlandini C. Role of epirubicin in advanced breast cancer. Clinical breast cancer. 2000 Sep 1;1:S46-51.

3.     Robert J. Clinical pharmacokinetics of epirubicin. Clinical pharmacokinetics. 1994 Jun;26(6):428-38.

4.     Erdem A, Ozsoz M. Interaction of the anticancer drug epirubicin with DNA. Analytica Chimica Acta. 2001 Jun 20;437(1):107-14.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Intas Pharmaceuticals Ltd

Address: Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad - 380009. Gujarat. India.

Country of origin: India